

09830923

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspat1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:37:04 ON 06 SEP 2006

Updated Search

09830923

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 14:38:25 ON 06 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4

DICTIONARY FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\opm.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:39:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 21638 TO ITERATE

9.2% PROCESSED 2000 ITERATIONS

2 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 423956 TO 441564

PROJECTED ANSWERS: 153 TO 711

L2 2 SEA SSS SAM L1

Updated Search

09830923

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 14:39:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 430544 TO ITERATE

100.0% PROCESSED 430544 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.08

L3 10 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.80

FILE 'HCAPLUS' ENTERED AT 14:39:39 ON 06 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Sep 2006 VOL 145 ISS 11

FILE LAST UPDATED: 5 Sep 2006 (20060905/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 13 L3

=> s l3/thu

13 L3

807993 THU/RL

L5 7 L3/THU

(L3 (L) THU/RL)

=> s l3/thu or l3/dma

13 L3

807993 THU/RL

7 L3/THU

(L3 (L) THU/RL)

13 L3

33445 DMA/RL

0 L3/DMA

(L3 (L) DMA/RL)

L6 7 L3/THU OR L3/DMA

Updated Search

09830923

=> s l3/thu or l3/dma or l3/pac or l3/pkt or l3/bac or l3/?therap? or l3/?drug? or l3/?pharm?

'?THERAP?' IS NOT A VALID CROSSOVER QUALIFIER FOR L3

Answer sets created in a different file may be field qualified with a limited set of qualifiers. Enter HELP CROSSOVER at an arrow prompt (=) for specific information.

=> s l3/pac

13 L3  
263518 PAC/RL  
L7 6 L3/PAC  
(L3 (L) PAC/RL)

=>

=> s l5 not l7

L8 3 L5 NOT L7

=> d l5, ibib abs hitstr, 1-7

L5 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:464621 HCAPLUS

DOCUMENT NUMBER: 144:488655

TITLE: Preparation of 8H-imidazo[4,5-d]thiazolo[4,5-b]pyridine derivatives as IKK inhibitors for treatment of inflammatory and immune diseases

INVENTOR(S): Dyckman, Alaric; Pitts, William J.; Belema, Makonen; Gill, Patrice; Kempson, James; Qiu, Yuping; Quesnelle, Claude; Spergel, Steven H.; Zusi, F. Christopher

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 67 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006106051	A1	20060518	US 2005-272401	20051110
WO 2006053120	A1	20060518	WO 2005-US40726	20051110
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-627761P P 20041112


OTHER SOURCE(S): MARPAT 144:488655

GI

Updated Search



I



II

AB The title 8H-imidazo[4,5-d]thiazolo[4,5-b]pyridine derivs. I [wherein R1 = H, alkyl, alkenyl, or alkynyl; R2 = H, halo, CN, (un)substituted alkyl, alkenyl, alkoxy, aryloxy, etc.; R3 = 3-substituted phenyl], or their enantiomers, diastereomers, and salts thereof were prepared as IKK inhibitors for the treatment of inflammatory and immune diseases. For example, II was prepared in a multi-step synthesis. The compds. showed inhibitory activity against IKK, I $\kappa$ B, NF- $\kappa$ B, and/or TNF- $\alpha$  (no data).

IT 887253-17-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazothiazolopyridine derivs. as IKK inhibitors for treatment of inflammatory and immune diseases)

RN 887253-17-0 HCAPLUS

CN 3-Pyridinecarboxamide, 2,6-dimethoxy-N-[(1S)-1-[3-(8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-2-yl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:912843 HCAPLUS

DOCUMENT NUMBER: 139:381756

TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua

PATENT ASSIGNEE(S): Schering Corporation, USA; Dendreon Corporation



Updated Search

09830923

SOURCE: U.S. Pat. Appl. Publ., 629 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003216325	A1	20031120	US 2001-908955	20010719
US 2004254117	A9	20041216		
US 7012066	B2	20060314		
CN 1498224	A	20040519	CN 2001-813111	20010719
ZA 2002010312	A	20040329	ZA 2002-10312	20021219
PRIORITY APPLN. INFO.:			US 2000-220108P	P 20000721
OTHER SOURCE(S):	MARPAT 139:381756			

GI



AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylaryl amino, arylamino, heteroaryl amino, cycloalkyl amino, or heterocycloalkyl amino; R1 is acyl; Z is O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH,

Updated Search

09830923

NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO<sub>2</sub>, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease. Thus, peptide II was prepared by the solid-phase method and showed  $K_i = 1-100$  nM (category A) in the HCV continuous assay.

IT 394720-42-4P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394720-42-4 HCAPLUS

CN Glycine, N-[(3,6-dimethoxy-2-pyridinyl)carbonyl]-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 2-propenyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

=CH<sub>2</sub>

REFERENCE COUNT: 111 THERE ARE 111 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591204 HCAPLUS

DOCUMENT NUMBER: 139:149928

TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girijavallabh, Viyyoor M.; Lovey,

Updated Search

09830923

Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, George F.; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Wong, Jesse K.; Nair, Latha G.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.; Dendreon Corp.

SOURCE: PCT Int. Appl., 633 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062265	A2	20030731	WO 2003-US1430	20030116
WO 2003062265	A3	20040916		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473032	AA	20030731	CA 2003-2473032	20030116
EP 1481000	A2	20041201	EP 2003-731956	20030116
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003006931	A	20050419	BR 2003-6931	20030116
CN 1633446	A	20050629	CN 2003-805933	20030116
JP 2005524628	T2	20050818	JP 2003-562142	20030116
NO 2004002792	A	20041015	NO 2004-2792	20040702
PRIORITY APPLN. INFO.:			US 2002-52386	A 20020118
			WO 2003-US1430	W 20030116

OTHER SOURCE(S): MARPAT 139:149928

GI



AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is selected from O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease. Thus, peptide II was prepared and showed  $K_i = 1-100$  nM (category A) in the HCV continuous assay.

IT 394720-42-4P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394720-42-4 HCAPLUS

CN Glycine, N-[(3,6-dimethoxy-2-pyridinyl)carbonyl]-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 2-propenyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


$$= \text{CH}_2$$

L5 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:90062 HCAPLUS

DOCUMENT NUMBER: 136:167698

TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S) : Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-Tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal N.; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marquerita; Tamura, Susan Y.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.  
SOURCE: PCT Int. Appl., 536 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008244	A2	20020131	WO 2001-US22678	20010719
WO 2002008244	A3	20030619		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,



RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

CA 2410662	AA	20020131	CA 2001-2410662	20010719
AU 2001076988	A5	20020205	AU 2001-76988	20010719
BR 2001012540	A	20030624	BR 2001-12540	20010719
EP 1385870	A2	20040204	EP 2001-954764	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004504404	T2	20040212	JP 2002-514149	20010719
CN 1498224	A	20040519	CN 2001-813111	20010719
NZ 523782	A	20051028	NZ 2001-523782	20010719
ZA 2002010312	A	20040329	ZA 2002-10312	20021219
NO 2003000272	A	20030321	NO 2003-272	20030120

US	2000-220108P	P	20000721
WO	2001-US22678	W	20010719

US	2000-220108P	P	20000721
WO	2001-US22678	W	20010719

US	2000-220108P	P	20000721
WO	2001-US22678	W	20010719



AB Peptides I were prepared wherein Y is alkyl, alkyl-aryl, heteroaryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy,, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino and heterocycloalkylamino; R1 is acyl, borate; Z is selected from O, N, CH or CR; W, Q, G, J, L, M independently maybe present or absent; W is C=O, C=S, C(=N-CN), or SO; Q is CH, N, P, alkylidene, O, amine,S, or SO; A is O, CH, alkylidene, amine, S, SO or bond; E is CH, N, alkylidene, or double bond; G is alkylidene; J is alkylidene, SO, NH, NR, O; L is CH, alkylidene, O, S or NR; M is O, NR,S, SO, alkylidene; p is 0 to 6; and R-R4 are independently selected from the

group consisting of H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halogen; (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease. Thus peptide II was prepared and tested as antiviral agent and NS3-serine protease inhibitors of hepatitis C virus with  $K_i$  ranges in category A = 1-100 nM; category B = 101-1,000 nM; category C > 1000 nM. Also disclosed is the use of I for the manufacture of a medicament for treating HCV, AIDS, and related disorders.

IT 394720-42-4P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394720-42-4 HCAPLUS

CN Glycine, N-[(3,6-dimethoxy-2-pyridinyl)carbonyl]-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

= CH<sub>2</sub>

L5 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:819241 HCAPLUS

DOCUMENT NUMBER: 132:64530



TITLE: Preparation of diacyl hydrazine compounds as protease

Updated Search

09830923

inhibitors  
 INVENTOR(S): Halbert, Stacie Marie; Michaud, Evelyne; Thompson, Scott Kevin; Veber, Daniel Frank  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 167 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966925	A1	19991229	WO 1999-US14561	19990624
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335876	AA	19991229	CA 1999-2335876	19990624
AU 9947237	A1	20000110	AU 1999-47237	19990624
EP 1093367	A1	20010425	EP 1999-930779	19990624
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2002518444	T2	20020625	JP 2000-555611	19990624
PRIORITY APPLN. INFO.:			US 1998-90493P	P 19980624
			WO 1999-US14561	W 19990624
OTHER SOURCE(S):			MARPAT 132:64530	
GI				



AB The present invention provides compds. I [L = C2-6 alkyl, Ar- or Het-C0-6 alkyl, CHR4NR5R6, CHR4Ar, CHR4OAr, NR4R7; X, Y, Z = N, O, S, CR10; R1, R2, R5, R10 = H, C1-6 alkyl, C2-6 alkenyl, Ar- or Het-C0-6 alkyl; R3 = C3-6 alkyl, Ar, Het, heterocycle Q, etc.; R4 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ar- or Het-C0-6 alkyl, etc.; R6 = R14 or an acyl group such as R14CO, R14C(S), R14OCO (R14 = C1-6 alkyl, C2-6 alkenyl, Ar- or Het C0-6 alkyl); R7 = C1-6 alkyl, C1-6 alkenyl, C3-6 cycloalkyl-, Ar-, or Het-C0-6 alkyl], which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis, gingival disease, and arthritis. Thus, N-[2-[N-cyclopropyl-N-(cyclopropylmethyl)amino]thiazol-4-ylcarbonyl]-N'-[N-(6-methyl-3-pyridinylmethoxycarbonyl)-L-β-tert-butylalanyl]hydrazide was prepared via sequential reactions of Et 6-nicotinate, L-β-tert-butylalanine, cyclopropylamine, cyclopropylcarboxaldehyde, benzoyl isothiocyanate, and Et bromopyruvate.

IT 253314-50-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic

Updated Search


09830923

use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of diacyl hydrazine compds. as protease inhibitors)

RN 253314-50-0 HCAPLUS

CN 4-Thiazolecarboxylic acid, 2-[cyclopropyl(2-methylpropyl)amino]-,  
2-[(2S)-2-[[[(2,6-dimethoxy-3-pyridinyl)carbonyl]amino]-4-methyl-1-oxopentyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:753058 HCAPLUS

DOCUMENT NUMBER: 132:426

TITLE: Diacyl carbohydrazide compounds as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation

INVENTOR(S): Halbert, Stacie Marie; Thompson, Scott Kevin; Veber, Daniel Frank

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959570	A1	19991125	WO 1998-US17275	19980820
W:	AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2332492	AA	19991125	CA 1998-2332492	19980820
AU 9891102	A1	19991206	AU 1998-91102	19980820
EP 1079821	A1	20010307	EP 1998-943273	19980820
R:	BE, CH, DE, ES, FR, GB, IT, LI, NL			
JP 2002515428	T2	20020528	JP 2000-549235	19980820
PRIORITY APPLN. INFO.:			US 1998-86553P	P 19980521
			WO 1998-US17275	W 19980820

OTHER SOURCE(S): MARPAT 132:426

AB The present invention provides diacyl carbohydrazide compds., and pharmaceutically acceptable salts, hydrates and solvates thereof, which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., novel intermediates of such compds., and methods for treating

Updated Search

diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.


IT 250726-27-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(diacyl carbohydrazide compds. as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation)

RN 250726-27-3 HCAPLUS

CN Benzeneacetic acid, 3-(2-pyridinyl)-, 2-[[2-[(2S)-2-[[2,6-dimethoxy-3-pyridinyl]carbonyl]amino]-4-methyl-1-oxopentyl]hydrazino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:268513 HCAPLUS

DOCUMENT NUMBER: 128:321945

TITLE: Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus NS3 protease  
INVENTOR(S): Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

09830923

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
GN, ML, MR, NE, SN, TD, TG

CA 2268391	AA	19980430	CA 1997-2268391	19971017
ZA 9709327	A	19980511	ZA 1997-9327	19971017
AU 9851477	A1	19980515	AU 1998-51477	19971017
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017
EP 932617	B1	20020116		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

IN 183120	A	19990911	IN 1997-CA1951	19971017
BR 9712544	A	19991019	BR 1997-12544	19971017
CN 1238780	A	19991215	CN 1997-180151	19971017
CN 1133649	B	20040107		
NZ 335276	A	20000929	NZ 1997-335276	19971017
JP 2001502694	T2	20010227	JP 1998-519568	19971017
EP 1136498	A1	20010926	EP 2001-109433	19971017

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

AP 1019	A	20011016	AP 1999-1512	19971017
---------	---	----------	--------------	----------

W: GH, KE, LS, MW, SD, SZ, UG, ZW




AT 212037	E	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
EE 4023	B1	20030415	EE 1999-161	19971017
TW 530065	B	20030501	TW 1997-86115382	19971018
NO 9901832	A	19990617	NO 1999-1832	19990416
US 6265380	B1	20010724	US 1999-293247	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417
HK 1023779	A1	20020927	HK 2000-100690	20000203
US 2002032175	A1	20020314	US 2001-875390	20010606
US 6617309	B2	20030909		
US 2004266731	A1	20041230	US 2003-607716	20030627

PRIORITY APPLN. INFO.:

US 1996-28290P	P	19961018
EP 1997-946273	A3	19971017
WO 1997-US18968	W	19971017
US 1999-293247	A	19990416
US 2001-875390	A3	20010606

OTHER SOURCE(S): MARPAT 128:321945

GI



AB The present invention relates to compds. I [ $\text{G1} = \text{SH}, \text{OH}, \text{SMe}, \text{alkenyl}, \text{alkynyl}, \text{CF}_3, \text{C1-2 alkoxy}, \text{C1-2 alkylthio}, (\text{un})\text{substituted C1-3 alkyl}; \text{W1} = \text{COCF}_2\text{CH}_2\text{N}(\text{G4})\text{U}, \text{CHO}, \text{COG}_2, \text{COCF}_2\text{CF}_3, \text{COCOG}_2, \text{COCO}_2\text{G}_2, \text{B}(\text{Q1})_2; \text{G}_2 = \text{alkyl}, \text{aryl}, \text{aralkyl}, (\text{un})\text{substituted mono-}, \text{bi-}, \text{or tricyclic heterocycle}; \text{G}_4 = \text{alkyl}, \text{alkenyl}, \text{alkynyl}, \text{cycloalkyl}, \text{cycloalkylalkyl}, \text{cycloalkylalkenyl}, \text{aryl}, \text{aralkyl}, \text{aralkenyl}, \text{etc.}; \text{Q1} = \text{OH}, \text{alkoxy}, \text{aryloxy}, \text{or Q1-Q1 form a 5-7 membered ring}; \text{U} = \text{H}, \text{G9CO}, \text{G9SO}_2, \text{G9COCO}, (\text{G9})_2\text{NCOCO}, (\text{G9})_2\text{NSO}_2, (\text{G9})_2\text{NCO}, \text{G9O}_2\text{C}; \text{G}_9 = \text{H}, \text{alkyl}, \text{carboxyalkyl}, \text{alkenyl}, \text{aryl}, \text{aralkyl}, \text{aralkenyl}, \text{cycloalkyl}, \text{heterocycloalkyl}, \text{etc.}; \text{or G9-G9 form a ring}; \text{E4} = \text{bond}, \alpha\text{-amino acid residue}, \text{heterocyclic amino acid}; \text{E5-E8} = \text{independently bond}, \text{amino acid residue}; 1\text{-2 peptide bonds between E5-E8 may be reduced}], \text{methods and pharmaceutical compns. for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compds., and the compns. and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus. Thus, peptide aldehyde II was prepared using solid-phase methods on a benzhydrylamine resin and tert-butoxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) protection starting from protected hydrazone III. Nearly 200 compds. I were prepared and tested for hepatitis C virus NS3 protease inhibitory activity, with II exhibiting  $\text{Ki} < 1 \mu\text{M}$  in an in vitro assay.$

IT 207001-81-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of peptide analogs as hepatitis C virus NS3 protease inhibitors)


RN 207001-81-8 HCAPLUS

CN L-Leucinamide, N-[(2,6-dimethoxy-3-pyridinyl)carbonyl]-L-valyl-L-valyl-N-

09830923

[(1S)-1-formylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:37:04 ON 06 SEP 2006)

FILE 'REGISTRY' ENTERED AT 14:38:25 ON 06 SEP 2006

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 10 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:39:39 ON 06 SEP 2006

L4 13 S L3

L5 7 S L3/THU

L6 7 S L3/THU OR L3/DMA

L7 6 S L3/PAC

L8 3 S L5 NOT L7

=> d l8, ibib abs hitstr, 1-3

L8 ANSWER 1 OF 3 HCAPLUS. COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:819241 HCAPLUS

DOCUMENT NUMBER: 132:64530

TITLE: Preparation of diacyl hydrazine compounds as protease inhibitors

INVENTOR(S): Halbert, Stacie Marie; Michaud, Evelyne; Thompson, Scott Kevin; Veber, Daniel Frank

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 167 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966925	A1	19991229	WO 1999-US14561	19990624

Updated Search

09830923


W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2335876	AA	19991229	CA 1999-2335876	19990624
AU 9947237	A1	20000110	AU 1999-47237	19990624
EP 1093367	A1	20010425	EP 1999-930779	19990624
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2002518444	T2	20020625	JP 2000-555611	19990624
PRIORITY APPLN. INFO.:			US 1998-90493P	P 19980624
			WO 1999-US14561	W 19990624

OTHER SOURCE(S): MARPAT 132:64530

GI



AB The present invention provides compds. I [L = C2-6 alkyl, Ar- or Het-C0-6 alkyl, CHR4NR5R6, CHR4Ar, CHR4OAr, NR4R7; X, Y, Z = N, O, S, CR10; R1, R2, R5, R10 = H, C1-6 alkyl, C2-6 alkenyl, Ar- or Het-C0-6 alkyl; R3 = C3-6 alkyl, Ar, Het, heterocycle Q, etc.; R4 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ar- or Het-C0-6 alkyl, etc.; R6 = R14 or an acyl group such as R14CO, R14C(S), R14OCO (R14 = C1-6 alkyl, C2-6 alkenyl, Ar- or Het C0-6 alkyl); R7 = C1-6 alkyl, C1-6 alkenyl, C3-6 cycloalkyl-, Ar-, or Het-C0-6 alkyl], which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis, gingival disease, and arthritis. Thus, N-[2-[N-cyclopropyl-N-(cyclopropylmethyl)amino]thiazol-4-ylcarbonyl]-N'-[N-(6-methyl-3-pyridinylmethoxycarbonyl)-L-β-tert-butylalanyl]hydrazide was prepared via sequential reactions of Et 6-nicotinate, L-β-tert-butylalanine, cyclopropylamine, cyclopropylcarboxaldehyde, benzoyl isothiocyanate, and Et bromopyruvate.

IT 253314-50-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of diacyl hydrazine compds. as protease inhibitors)


RN 253314-50-0 HCAPLUS

CN 4-Thiazolecarboxylic acid, 2-[cyclopropyl(2-methylpropyl)amino]-, 2-[(2S)-2-[[[(2,6-dimethoxy-3-pyridinyl)carbonyl]amino]-4-methyl-1-oxopentyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

09830923



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:753058 HCAPLUS  
DOCUMENT NUMBER: 132:426  
TITLE: Diacyl carbohydrazide compounds as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation  
INVENTOR(S): Halbert, Stacie Marie; Thompson, Scott Kevin; Veber, Daniel Frank  
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 74 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959570	A1	19991125	WO 1998-US17275	19980820
W:	AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2332492	AA	19991125	CA 1998-2332492	19980820
AU 9891102	A1	19991206	AU 1998-91102	19980820
EP 1079821	A1	20010307	EP 1998-943273	19980820
R:	BE, CH, DE, ES, FR, GB, IT, LI, NL			
JP 2002515428	T2	20020528	JP 2000-549235	19980820
PRIORITY APPLN. INFO.:			US 1998-86553P	P 19980521
			WO 1998-US17275	W 19980820

OTHER SOURCE(S): MARPAT 132:426

AB The present invention provides diacyl carbohydrazide compds., and pharmaceutically acceptable salts, hydrates and solvates thereof, which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., novel intermediates of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

IT 250726-27-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

Updated Search


09830923

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (diacyl carbohydrazide compds. as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation)

RN 250726-27-3 HCAPLUS

CN Benzeneacetic acid, 3-(2-pyridinyl)-, 2-[[2-[(2S)-2-[[[(2,6-dimethoxy-3-pyridinyl)carbonyl]amino]-4-methyl-1-oxopentyl]hydrazino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:268513 HCAPLUS

DOCUMENT NUMBER: 128:321945

TITLE: Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus NS3 protease  
INVENTOR(S): Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2268391	AA	19980430	CA 1997-2268391	19971017
ZA 9709327	A	19980511	ZA 1997-9327	19971017
AU 9851477	A1	19980515	AU 1998-51477	19971017
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017
EP 932617	B1	20020116		

Updated Search

09830923

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

IN 183120	A	19990911	IN 1997-CA1951	19971017
BR 9712544	A	19991019	BR 1997-12544	19971017
CN 1238780	A	19991215	CN 1997-180151	19971017
CN 1133649	B	20040107		
NZ 335276	A	20000929	NZ 1997-335276	19971017
JP 2001502694	T2	20010227	JP 1998-519568	19971017
EP 1136498	A1	20010926	EP 2001-109433	19971017

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

AP 1019	A	20011016	AP 1999-1512	19971017
---------	---	----------	--------------	----------

W: GH, KE, LS, MW, SD, SZ, UG, ZW




AT 212037	E	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
EE 4023	B1	20030415	EE 1999-161	19971017
TW 530065	B	20030501	TW 1997-86115382	19971018
NO 9901832	A	19990617	NO 1999-1832	19990416
US 6265380	B1	20010724	US 1999-293247	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417
HK 1023779	A1	20020927	HK 2000-100690	20000203
US 2002032175	A1	20020314	US 2001-875390	20010606
US 6617309	B2	20030909		
US 2004266731	A1	20041230	US 2003-607716	20030627

PRIORITY APPLN. INFO.:

US 1996-28290P	P	19961018
EP 1997-946273	A3	19971017
WO 1997-US18968	W	19971017
US 1999-293247	A	19990416
US 2001-875390	A3	20010606

OTHER SOURCE(S): MARPAT 128:321945

GI



AB The present invention relates to compds. I [G1 = SH, OH, SMe, alkenyl, alkynyl, CF3, C1-2 alkoxy, C1-2 alkylthio, (un)substituted C1-3 alkyl; W1 = COCF2CH2N(G4)U, CHO, COG2, COCF2CF3, COCOG2, COCO2G2, B(Q1)2; G2 = alkyl, aryl, aralkyl, (un)substituted mono-, bi-, or tricyclic heterocycle; G4 = alky, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, etc.; Q1 = OH, alkoxy, aryloxy, or Q1-Q1 form a 5-7 membered ring; U = H, G9CO, G9SO2, G9COCO, (G9)2NCOCO, (G9)2NSO2, (G9)2NCO, G9O2C; G9 = H, alkyl, carboxyalkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, heterocycloalkyl, etc; or G9-G9 form a ring; E4 = bond,  $\alpha$ -amino acid residue, heterocyclic amino acid; E5-E8 = independently bond, amino acid residue; 1-2 peptide bonds between E5-E8 may be reduced], methods and pharmaceutical compns. for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compds., and the compns. and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus. Thus, peptide aldehyde II was prepared using solid-phase methods on a benzhydrylamine resin and tert-butoxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) protection starting from protected hydrazone III. Nearly 200 compds. I were prepared and tested for hepatitis C virus NS3 protease inhibitory activity, with II exhibiting Ki <1  $\mu$ M in an in vitro assay.

IT 207001-81-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of peptide analogs as hepatitis C virus NS3 protease inhibitors)


RN 207001-81-8 HCAPLUS

CN L-Leucinamide, N-[(2,6-dimethoxy-3-pyridinyl)carbonyl]-L-valyl-L-valyl-N-

09830923

[(1S)-1-formylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:37:04 ON 06 SEP 2006)

FILE 'REGISTRY' ENTERED AT 14:38:25 ON 06 SEP 2006

L1 STRUCTURE UPLOADED  
L2 2 S L1  
L3 10 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:39:39 ON 06 SEP 2006

L4 13 S L3  
L5 7 S L3/THU  
L6 7 S L3/THU OR L3/DMA  
L7 6 S L3/PAC  
L8 3 S L5 NOT L7

=> s l3/pkt

13 L3  
33607 PKT/RL  
L9 0 L3/PKT  
(L3 (L) PKT/RL)

=> s l3/bac

13 L3  
1017580 BAC/RL  
L10 3 L3/BAC  
(L3 (L) BAC/RL)

=> s l10 not l8

L11 0 L10 NOT L8

=> s l3/?therap?

'?THERAP?' IS NOT A VALID CROSSOVER QUALIFIER FOR L3

Answer sets created in a different file may be field qualified with a limited set of qualifiers. Enter HELP CROSSOVER at an arrow prompt (=) for specific information.

Updated Search

09830923

=> s l3 and ?therap?

13 L3

559034 ?THERAP?

L12

1 L3 AND ?THERAP?

=> d l12, ibib abs hitstr, 1

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:753058 HCAPLUS

DOCUMENT NUMBER: 132:426

TITLE: Diacyl carbohydrazide compounds as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation

INVENTOR(S): Halbert, Stacie Marie; Thompson, Scott Kevin; Veber, Daniel Frank

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959570	A1	19991125	WO 1998-US17275	19980820
W:	AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2332492	AA	19991125	CA 1998-2332492	19980820
AU 9891102	A1	19991206	AU 1998-91102	19980820
EP 1079821	A1	20010307	EP 1998-943273	19980820
R:	BE, CH, DE, ES, FR, GB, IT, LI, NL			
JP 2002515428	T2	20020528	JP 2000-549235	19980820
PRIORITY APPLN. INFO.:			US 1998-86553P	P 19980521
			WO 1998-US17275	W 19980820

OTHER SOURCE(S): MARPAT 132:426

AB The present invention provides diacyl carbohydrazide compds., and pharmaceutically acceptable salts, hydrates and solvates thereof, which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., novel intermediates of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

IT 250726-27-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(diacyl carbohydrazide compds. as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation)

Updated Search

09830923

RN 250726-27-3 HCAPLUS  
CN Benzeneacetic acid, 3-(2-pyridinyl)-, 2-[[2-[(2S)-2-[[2,6-dimethoxy-3-pyridinyl)carbonyl]amino]-4-methyl-1-oxopentyl]hydrazino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:37:04 ON 06 SEP 2006)

FILE 'REGISTRY' ENTERED AT 14:38:25 ON 06 SEP 2006

L1 STRUCTURE UPLOADED  
L2 2 S L1  
L3 10 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:39:39 ON 06 SEP 2006

L4 13 S L3  
L5 7 S L3/THU  
L6 7 S L3/THU OR L3/DMA  
L7 6 S L3/PAC  
L8 3 S L5 NOT L7  
L9 0 S L3/PKT  
L10 3 S L3/BAC  
L11 0 S L10 NOT L8  
L12 1 S L3 AND ?THERAP?

=> s l3 and ?drug?

13 L3  
840846 ?DRUG?  
L13 4 L3 AND ?DRUG?

=> s l13 not l5

L14 3 L13 NOT L5

=> s l14 not l10

L15 3 L14 NOT L10

=> d l15, ibib abs hitstr, 1-3

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:193407 HCAPLUS  
DOCUMENT NUMBER: 144:273163  
TITLE: Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste

Updated Search

09830923

enhancers  
 INVENTOR(S): Tachdjian, Catherine; Patron, Andrew P.; Qi, Ming;  
 Adamski-Werner, Sara L.; Tang, Xiao-Qing; Chen, Qing;  
 Darmohusodo, Vincent; Lebl-Rinnova, Marketa; Priest,  
 Chad  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 168 pp., Cont.-in-part of U.S.  
 Ser. No. 913,303.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006045953	A1	20060302	US 2005-51567	20050204
US 2005084506	A1	20050421	US 2004-913303	20040806
WO 2005041684	A2	20050512	WO 2004-US25419	20040806
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2006084246	A2	20060810	WO 2006-US4132	20060206
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:  
 US 2004-913303 A2 20040806  
 WO 2004-US25419 A2 20040806  
 US 2003-494071P P 20030806  
 US 2004-552064P P 20040309  
 US 2005-51567 A 20050204

OTHER SOURCE(S): MARPAT 144:273163

AB Non-natural amide compds. added to food, beverages, or pharmaceuticals at concns. preferably on the order of 100 ppm or lower may serve as savory (umami) or sweet taste modifiers, savory or sweet flavoring agents, and savory or sweet flavor enhancers. They may also act in the presence of, or in mixts. with, conventional flavoring agents such as monosodium glutamate or known natural and artificial sweeteners. Thus, 3  $\mu$ M N1-(2,4-dimethoxybenzyl)-N2-(2-(pyridin-2-yl)ethyl)oxalamide enhanced the savory taste of glutamate in low-sodium tomato juice by 1.4 to 1.5-fold.

IT 851669-82-4P

RL: FFD (Food or feed use); PAC (Pharmacological activity); PRP

Updated Search


09830923

(Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(aromatic amides and ureas as sweetness or umami flavor modifiers)

RN 851669-82-4 HCAPLUS

CN D-Leucine, N-[(2,6-dimethoxy-4-pyridinyl)carbonyl]-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:405341 HCAPLUS

DOCUMENT NUMBER: 142:462667

TITLE: Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

INVENTOR(S): Tachdjian, Catherine; Patron, Andrew P.; Adamski-Werner, Sara L.; Bakir, Farid; Chen, Qing; Darmohusodo, Vincent; Hobson, Stephen Terrence; Li, Xiadong; Qi, Ming; Rogers, Daniel Harry; Rinnova, Marketa; Servant, Guy; Tang, Xiao-Qing; Zoller, Mark; Wallace, Mark; Xing, Amy; Gubernator, Klaus

PATENT ASSIGNEE(S): Senomyx Inc., USA

SOURCE: PCT Int. Appl., 262 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041684	A2	20050512	WO 2004-US25419	20040806
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004285410	A1	20050512	AU 2004-285410	20040806
CA 2535036	AA	20050512	CA 2004-2535036	20040806
EP 1659881	A2	20060531	EP 2004-816798	20040806

Updated Search

09830923

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
US 2006045953 A1 20060302 US 2005-51567 20050204  
PRIORITY APPLN. INFO.: US 2003-494071P P 20030806  
US 2004-552064P P 20040309  
US 2004-913303 A2 20040806  
WO 2004-US25419 W 20040806

OTHER SOURCE(S): MARPAT 142:462667

AB Flavor or taste modifiers, such as a flavoring or flavoring agents and  
flavor or trite enhancer, more particularly, savory (the 'umami' taste of  
monosodium glutamate) or sweet taste modifiers, - savory or sweet  
flavoring agents and savory or sweet flavor enhancers, were prepared for  
food, beverages, and other comestible or orally administered medicinal  
products or compns. Thus, non-naturally occurring, non-peptide arride  
compds. and amide derivs., such as oxalamides, ureas, and acrylamides,  
were prepared


IT 851669-82-4P

RL: FFD (Food or feed use); PAC (Pharmacological activity); PRP  
(Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(flavors, flavor modifiers, tastants, taste enhancers, umami or sweet  
tastants, and/or enhancers and their use)

RN 851669-82-4 HCAPLUS

CN D-Leucine, N-[(2,6-dimethoxy-4-pyridinyl)carbonyl]-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1967:482064 HCAPLUS

DOCUMENT NUMBER: 67:82064

TITLE: Drugs from  $\beta$ -phenylisopropylamines. I.  
Derivatives containing a pyridine ring

AUTHOR(S): Kudryashova, N. I.; Khromov-Borisov, N. V.

CORPORATE SOURCE: Inst. Eksperim. Med. Akad. Med. Nauk., Leningrad, USSR

SOURCE: Zhurnal Organicheskoi Khimii (1967), 3(6), 1117-21  
CODEN: ZORKAE; ISSN: 0514-7492

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB A series of the title compds. of general formula  $\text{PhCH}_2\text{CMeHNHR}$  (I) was  
synthesized. Compds. I (R = isonicotinyl) and I (R = 4-pyridyl) have  
sedative and hypotensive activities. The compds. were prepared by treating  
2-R1-substituted, 6-R2-substituted isonicotinyl chloride (II) with  
 $\text{PhCH}_2\text{CMeHNH}_2$ . For example, to 15 g. isonicotinic acid 45 ml.  $\text{SOCl}_2$  was  
added slowly. The mixture was boiled to dissolve all the solids and evaporated  
to dryness in vacuum. The residue was dissolved in 60 ml. anhydrous benzene

Updated Search

09830923

and 55 ml. PhCH<sub>2</sub>CMeHNH<sub>2</sub> was added slowly. The mixture was refluxed 3 hrs., washed with water, dried with K<sub>2</sub>CO<sub>3</sub>, and evaporated in vacuo. The residue was crystallized from MeOH to give 50.6% I (R = isonicotinyl) m. 11-12.5°

(HCl salt m. 92-4°). II (R<sub>1</sub> = R<sub>2</sub> = Cl), m. 208-9°

(alc.-water), was prepared in 91% yield by action of POCl<sub>3</sub> on II (R<sub>1</sub> = R<sub>2</sub> = OH). Heating II (R<sub>1</sub> = R<sub>2</sub> = Cl) with NaOMe gave 93.3% II (R<sub>1</sub> = Cl, R<sub>2</sub> = OMe) m. 212-13° (alc.-water), and II (R<sub>1</sub> = R<sub>2</sub> = OMe), m.

226.5-28° (MeOH) (yield not given). Treating II with PhCH<sub>2</sub>CMeHNH<sub>2</sub>

gave the following I (R, % yield, and m.p. given): 2,6-

dichloroisonicotinyl, 96.3, 137.5-38° (alc.-water);

2,6-dimethoxyisonicotinyl, 62, 88-91° (AcMe); 2-chloro-6-

methoxyisonicotinyl, 60.8, 102-4° (alc.-water). Reaction of

cinchoninyl chloride (prepared in situ from cinchoninic acid and SOCl<sub>2</sub>) with

PhCH<sub>2</sub>CMeHNH<sub>2</sub> gave 74.1% I (R = cinchoninyl), m. 140-4°

(alc.-water). (HCl salt m. 205-7°). Similarly, I (R =

9-acridinylcarbonyl), m. 200-2° (alc.-water) (yield 84.5%) (HCl

salt m. 282-3°) was prepared Heating a mixture of 2.85 g. I (R =

2,6-dichloroisonicotinyl) and 15 ml. Et<sub>2</sub>NH in a sealed tube 15 hrs. at

195-200° gave 70.1% I (R = 2,6-diethylaminoisonicotinyl), m.

167-9° (AcMe). The above sealed-tube reaction with .apprx.1/2 the

amount of Et<sub>2</sub>NH gave 89.6% I (R = 2-chloro-6-ethylaminoisonicotinyl), m.

136-7° (alc.-water). Refluxing 2 hrs. at 200-5° a mixture of

6.05 g. PhCH<sub>2</sub>CMeHNH<sub>2</sub>.HCl with 6.22 g. 4-phenoxy pyridine, followed by

dissoln. in water, steam distillation (to remove PhCH<sub>2</sub>CMeHNH<sub>2</sub>), acidification,

2nd steam distillation (to remove PhOH), neutralization, and crystallization

of the organic

layer gave 55.7% I (R = 4-pyridyl), m. 122-3° (alc.-water).

IT 15855-04-6P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 15855-04-6 HCAPLUS

CN Isonicotinamide, 2,6-dimethoxy-N-(α-methylphenethyl)- (8CI) (CA

INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:37:04 ON 06 SEP 2006)

FILE 'REGISTRY' ENTERED AT 14:38:25 ON 06 SEP 2006

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 10 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:39:39 ON 06 SEP 2006

L4 13 S L3

L5 7 S L3/THU

Updated Search

09830923

L6 7 S L3/THU OR L3/DMA  
L7 6 S L3/PAC  
L8 3 S L5 NOT L7  
L9 0 S L3/PKT  
L10 3 S L3/BAC  
L11 0 S L10 NOT L8  
L12 1 S L3 AND ?THERAP?  
L13 4 S L3 AND ?DRUG?  
L14 3 S L13 NOT L5  
L15 3 S L14 NOT L10

=> s l10 and ?pharm?  
587427 ?PHARM?

L16 3 L10 AND ?PHARM?

=> d l16, ibib abs hitstr, 1-3

L16 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:819241 HCAPLUS

DOCUMENT NUMBER: 132:64530

TITLE: Preparation of diacyl hydrazine compounds as protease inhibitors

INVENTOR(S): Halbert, Stacie Marie; Michaud, Evelyne; Thompson, Scott Kevin; Veber, Daniel Frank

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 167 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966925	A1	19991229	WO 1999-US14561	19990624
W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2335876	AA	19991229	CA 1999-2335876	19990624
AU 9947237	A1	20000110	AU 1999-47237	19990624
EP 1093367	A1	20010425	EP 1999-930779	19990624
R:	BE, CH, DE, ES, FR, GB, IT, LI, NL			
JP 2002518444	T2	20020625	JP 2000-555611	19990624
PRIORITY APPLN. INFO.:			US 1998-90493P	P 19980624
			WO 1999-US14561	W 19990624

OTHER SOURCE(S): MARPAT 132:64530

GI




Updated Search

AB The present invention provides compds. I [L = C2-6 alkyl, Ar- or Het-C0-6 alkyl, CHR4NR5R6, CHR4Ar, CHR4OAr, NR4R7; X, Y, Z = N, O, S, CR10; R1, R2, R5, R10 = H, C1-6 alkyl, C2-6 alkenyl, Ar- or Het-C0-6 alkyl; R3 = C3-6 alkyl, Ar, Het, heterocycle Q, etc.; R4 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ar- or Het-C0-6 alkyl, etc.; R6 = R14 or an acyl group such as R14CO, R14C(S), R14OCO (R14 = C1-6 alkyl, C2-6 alkenyl, Ar- or Het C0-6 alkyl); R7 = C1-6 alkyl, C1-6 alkenyl, C3-6 cycloalkyl-, Ar-, or Het-C0-6 alkyl], which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis, gingival disease, and arthritis. Thus, N-[2-[N-cyclopropyl-N-(cyclopropylmethyl)amino]thiazol-4-ylcarbonyl]-N'-[N-(6-methyl-3-pyridinylmethoxycarbonyl)-L- $\beta$ -tert-butylalanyl]hydrazide was prepared via sequential reactions of Et 6-nicotinate, L- $\beta$ -tert-butylalanine, cyclopropylamine, cyclopropylcarboxaldehyde, benzoyl isothiocyanate, and Et bromopyruvate.

IT 253314-50-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of diacyl hydrazine compds. as protease inhibitors)

RN 253314-50-0 HCAPLUS  
 CN 4-Thiazolecarboxylic acid, 2-[cyclopropyl(2-methylpropyl)amino]-, 2-[(2S)-2-[[[(2,6-dimethoxy-3-pyridinyl)carbonyl]amino]-4-methyl-1-oxopentyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1999:753058 HCAPLUS  
 DOCUMENT NUMBER: 132:426  
 TITLE: Diacyl carbohydrazide compounds as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation  
 INVENTOR(S): Halbert, Stacie Marie; Thompson, Scott Kevin; Veber, Daniel Frank  
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 74 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
WO 9959570          A1      19991125      WO 1998-US17275          19980820
W:  AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP,
    KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG,
    SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD,
    RU, TJ, TM
RW:  GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
    FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
    CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2332492          AA      19991125      CA 1998-2332492          19980820
AU 9891102          A1      19991206      AU 1998-91102          19980820
EP 1079821          A1      20010307      EP 1998-943273        19980820
R:   BE, CH, DE, ES, FR, GB, IT, LI, NL
JP 2002515428      T2      20020528      JP 2000-549235        19980820
PRIORITY APPLN. INFO.:      US 1998-86553P        P 19980521
                                WO 1998-US17275        W 19980820

```

OTHER SOURCE(S):            MARPAT 132:426

AB    The present invention provides diacyl carbohydrazide compds., and pharmaceutically acceptable salts, hydrates and solvates thereof, which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., novel intermediates of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

IT    250726-27-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(diacyl carbohydrazide compds. as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation)

RN    250726-27-3    HCAPLUS

CN    Benzeneacetic acid, 3-(2-pyridinyl)-, 2-[[2-[(2S)-2-[[[(2,6-dimethoxy-3-pyridinyl)carbonyl]amino]-4-methyl-1-oxopentyl]hydrazino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:            5            THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 3    HCAPLUS    COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:            1998:268513    HCAPLUS

DOCUMENT NUMBER:            128:321945

TITLE:                        Preparation of peptide analogs as inhibitors of serine




Updated Search

proteases, particularly hepatitis C virus NS3 protease  
 INVENTOR(S): Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.  
 SOURCE: PCT Int. Appl., 128 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2268391	AA	19980430	CA 1997-2268391	19971017
ZA 9709327	A	19980511	ZA 1997-9327	19971017
AU 9851477	A1	19980515	AU 1998-51477	19971017
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017
EP 932617	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 183120	A	19990911	IN 1997-CA1951	19971017
BR 9712544	A	19991019	BR 1997-12544	19971017
CN 1238780	A	19991215	CN 1997-180151	19971017
CN 1133649	B	20040107		
NZ 335276	A	20000929	NZ 1997-335276	19971017
JP 2001502694	T2	20010227	JP 1998-519568	19971017
EP 1136498	A1	20010926	EP 2001-109433	19971017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AP 1019	A	20011016	AP 1999-1512	19971017
W: GH, KE, LS, MW, SD, SZ, UG, ZW				
AT 212037	E	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
EE 4023	B1	20030415	EE 1999-161	19971017
TW 530065	B	20030501	TW 1997-86115382	19971018
NO 9901832	A	19990617	NO 1999-1832	19990416
US 6265380	B1	20010724	US 1999-293247	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417
HK 1023779	A1	20020927	HK 2000-100690	20000203
US 2002032175	A1	20020314	US 2001-875390	20010606
US 6617309	B2	20030909		
US 2004266731	A1	20041230	US 2003-607716	20030627
PRIORITY APPLN. INFO.:			US 1996-28290P	P 19961018
			EP 1997-946273	A3 19971017
			WO 1997-US18968	W 19971017
			US 1999-293247	A 19990416

OTHER SOURCE(S) :  
GI

MARPAT 128:321945



AB The present invention relates to compds. I [G1 = SH, OH, SMe, alkenyl, alkynyl, CF<sub>3</sub>, C1-2 alkoxy, C1-2 alkylthio, (un)substituted C1-3 alkyl; W1 = COCF<sub>2</sub>CH<sub>2</sub>N(G4)U, CHO, COG<sub>2</sub>, COCF<sub>2</sub>CF<sub>3</sub>, COCOG<sub>2</sub>, COCO<sub>2</sub>G<sub>2</sub>, B(Q1)<sub>2</sub>; G<sub>2</sub> = alkyl, aryl, aralkyl, (un)substituted mono-, bi-, or tricyclic heterocycle; G<sub>4</sub> = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, etc.; Q1 = OH, alkoxy, aryloxy, or Q1-Q1 form a 5-7 membered ring; U = H, G<sub>9</sub>CO, G<sub>9</sub>SO<sub>2</sub>, G<sub>9</sub>COCO, (G<sub>9</sub>)<sub>2</sub>NCOCO, (G<sub>9</sub>)<sub>2</sub>NSO<sub>2</sub>, (G<sub>9</sub>)<sub>2</sub>NCO, G<sub>9</sub>O<sub>2</sub>C; G<sub>9</sub> = H, alkyl, carboxyalkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, heterocycloalkyl, etc; or G<sub>9</sub>-G<sub>9</sub> form a ring; E<sub>4</sub> = bond, α-amino acid residue, heterocyclic amino acid; E<sub>5</sub>-E<sub>8</sub> = independently bond, amino acid residue; 1-2 peptide bonds between E<sub>5</sub>-E<sub>8</sub> may be reduced], methods and pharmaceutical compns. for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compds., and the compns. and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus. Thus, peptide aldehyde II was prepared using solid-phase methods on a benzhydrylamine resin and tert-butoxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) protection starting from protected hydrazone III. Nearly 200 compds. I were prepared and tested for hepatitis C virus NS3 protease inhibitory activity, with II exhibiting Ki <1 μM in an in vitro assay.

IT 207001-81-8P

RL: BAC (Biological activity or effector, except adverse); BSU


09830923

(Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of peptide analogs as hepatitis C virus NS3 protease inhibitors)

RN 207001-81-8 HCAPLUS

CN L-Leucinamide, N-[(2,6-dimethoxy-3-pyridinyl)carbonyl]-L-valyl-L-valyl-N-[(1S)-1-formylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Updated Search

7 8 9 11 13 14 15 16 18 22 25 32 39 40 41 42 43 46

ring nodes :

1 2 3 4 5 6 26 27 28 29 30 31 33 34 35 36 37 38

chain bonds :

7-8 7-9 11-46 13-14 15-16 16-18 25-28 32-35 32-39 41-42 42-43

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31 33-34 33-38 34-35 35-36 36-37  
37-38

exact/norm bonds :

7-8 7-9 11-46 13-14 15-16 16-18 41-42 42-43

exact bonds :

25-28 32-35 32-39

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31 33-34 33-38 34-35 35-36 36-37  
37-38

isolated ring systems :

containing 1 : 26 : 33 :

G1:[\*1],[\*2]


G2:[\*3],[\*4],[\*5],[\*6]

### Connectivity :

14:1 E exact RC ring/chain 40:1 E exact RC ring/chain 41:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:Atom 11:CLASS12:Atom  
13:CLASS14:CLASS15:CLASS16:CLASS18:CLASS22:CLASS23:Atom 25:CLASS26:Atom 27:Atom 28:Atom  
29:Atom 30:Atom 31:Atom 32:CLASS33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:CLASS  
40:CLASS41:CLASS42:CLASS43:CLASS46:CLASS



chain nodes :

7 8 9 11 13 14 15 16 18 22 25 32 39 40 41 42 43 46 50 51

ring nodes :

1 2 3 4 5 6 26 27 28 29 30 31 33 34 35 36 37 38

chain bonds :

7-8 7-9 9-50 11-46 13-14 15-16 16-18 25-28 32-35 32-39 41-42 42-43 50-51

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31 33-34 33-38 34-35 35-36 36-37 37-38

exact/norm bonds :

7-8 7-9 11-46 13-14 15-16 16-18 41-42 42-43

exact bonds :

9-50 25-28 32-35 32-39 50-51

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31 33-34 33-38 34-35 35-36 36-37 37-38

isolated ring systems :

containing 1 : 26 : 33 :


G1:[\*1],[\*2]

G2:[\*3],[\*4],[\*5],[\*6]

Connectivity :

14:1 E exact RC ring/chain 40:1 E exact RC ring/chain 41:1 E exact RC ring/chain  
Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:Atom 11:CLASS12:Atom  
13:CLASS14:CLASS15:CLASS16:CLASS18:CLASS22:CLASS23:Atom 25:CLASS26:Atom 27:Atom 28:Atom  
29:Atom 30:Atom 31:Atom 32:CLASS33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:CLASS  
40:CLASS41:CLASS42:CLASS43:CLASS46:CLASS50:CLASS51:CLASS



chain nodes :

7 8 9 11 13 14 15 16 18 22 25 32 39 40 41 42 43 46 50 51

ring nodes :

1 2 3 4 5 6 26 27 28 29 30 31 33 34 35 36 37 38

chain bonds :

7-8 7-9 9-50 11-46 13-14 15-16 16-18 25-28 32-35 32-39 41-42 42-43 50-51

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31 33-34 33-38 34-35 35-36 36-37 37-38

exact/norm bonds :

7-8 7-9 9-50 11-46 13-14 15-16 16-18 41-42 42-43

exact bonds :

25-28 32-35 32-39 50-51

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31 33-34 33-38 34-35 35-36 36-37 37-38

isolated ring systems :

containing 1 : 26 : 33 :

G1:[\*1],[\*2]

G2:[\*3],[\*4],[\*5],[\*6]

Connectivity :

14:1 E exact RC ring/chain 40:1 E exact RC ring/chain 41:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:Atom 11:CLASS12:Atom  
13:CLASS14:CLASS15:CLASS16:CLASS18:CLASS22:CLASS23:Atom 25:CLASS26:Atom 27:Atom 28:Atom  
29:Atom 30:Atom 31:Atom 32:CLASS33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:CLASS  
40:CLASS41:CLASS42:CLASS43:CLASS46:CLASS50:CLASS51:CLASS

09830923

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 5 MAY 11 KOREAPAT updates resume  
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFULL/USPAT2  
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 13 JUL 14 FSTA enhanced with Japanese patents  
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 17 AUG 30 CA(SM)/CAPLUS(SM) Austrian patent law changes  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:42:01 ON 06 SEP 2006

Updated Search

09830923

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:42:08 ON 06 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4

DICTIONARY FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\ety.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:45:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 50327 TO ITERATE

4.0% PROCESSED 2000 ITERATIONS

2 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 993157 TO 1019923

PROJECTED ANSWERS: 581 TO 1431

L2 2 SEA SSS SAM L1

Updated Search

09830923

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\poi.str

L3           STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3           STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 11:49:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -       6920 TO ITERATE

28.9% PROCESSED       2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE   \*\*COMPLETE\*\*  
                          BATCH   \*\*COMPLETE\*\*

PROJECTED ITERATIONS:       133413 TO   143387

PROJECTED ANSWERS:           0 TO       0

L4           0 SEA SSS SAM L3

=> s l3 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 11:49:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -   138330 TO ITERATE

100.0% PROCESSED   138330 ITERATIONS  
SEARCH TIME: 00.00.02

0 ANSWERS

L5           0 SEA SSS FUL L3

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\poia.str

L6           STRUCTURE UPLOADED

=> d l6

L6 HAS NO ANSWERS

L6           STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l6

SAMPLE SEARCH INITIATED 11:53:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -   26910 TO ITERATE

7.4% PROCESSED       2000 ITERATIONS

2 ANSWERS

Updated Search

09830923

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 528388 TO 548012  
PROJECTED ANSWERS: 227 TO 849

L7 2 SEA SSS SAM L6

=> s l6 full  
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 11:53:59 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 536371 TO ITERATE

100.0% PROCESSED 536371 ITERATIONS 383 ANSWERS  
SEARCH TIME: 00.00.07

L8 383 SEA SSS FUL L6

=> file hcaplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 341.80 342.01

FILE 'HCAPLUS' ENTERED AT 11:54:10 ON 06 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Sep 2006 VOL 145 ISS 11  
FILE LAST UPDATED: 5 Sep 2006 (20060905/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l8  
L9 139 L8

=> file reg  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 7.59 349.60

FILE 'REGISTRY' ENTERED AT 11:55:51 ON 06 SEP 2006

Updated Search

09830923

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4  
DICTIONARY FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\65656.str

L10 STRUCTURE UPLOADED

=> d l10

L10 HAS NO ANSWERS

L10 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l10

SAMPLE SEARCH INITIATED 11:58:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 20884 TO ITERATE

9.6% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 409030 TO 426330  
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L10

=> s l10 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 11:58:14 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 416172 TO ITERATE

Updated Search

09830923

100.0% PROCESSED 416172 ITERATIONS  
SEARCH TIME: 00.00.04

0 ANSWERS

L12 0 SEA SSS FUL L10

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\opm.str

L13 STRUCTURE UPLOADED

=> s l13

SAMPLE SEARCH INITIATED 12:01:50 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 21638 TO ITERATE

9.2% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 423956 TO 441564  
PROJECTED ANSWERS: 153 TO 711

L14 2 SEA SSS SAM L13

=> s l13 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 12:01:57 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 430544 TO ITERATE

100.0% PROCESSED 430544 ITERATIONS  
SEARCH TIME: 00.00.05

10 ANSWERS

L15 10 SEA SSS FUL L13

=> s l14 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 12:02:11 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 430544 TO ITERATE

100.0% PROCESSED 430544 ITERATIONS  
SEARCH TIME: 00.00.04

10 ANSWERS

L16 10 SEA SSS FUL L13

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

504.34

853.94

FILE 'HCAPLUS' ENTERED AT 12:02:18 ON 06 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

Updated Search

09830923

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Sep 2006 VOL 145 ISS 11  
FILE LAST UPDATED: 5 Sep 2006 (20060905/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l15

L17 13 L15

=> s l17 and imamura, k?/au

1427 IMAMURA, K?/AU

L18 0 L17 AND IMAMURA, K?/AU

=> s l17 and mitomo, k?/au

43 MITOMO, K?/AU

L19 0 L17 AND MITOMO, K?/AU

=> s l17 and yamada, n?/au

3789 YAMADA, N?/AU

L20 0 L17 AND YAMADA, N?/AU

=> s l17 and teraoka, t?/au

382 TERAOKA, T?/AU

L21 0 L17 AND TERAOKA, T?/AU

=> s l17 and sakanaka, o?/au

25 SAKANAKA, O?/AU

L22 0 L17 AND SAKANAKA, O?/AU

=> s l17 and kurihara, h?/au

1421 KURIHARA, H?/AU

L23 0 L17 AND KURIHARA, H?/AU

=> s l17 and taniguchi, m?/au

3956 TANIGUCHI, M?/AU

L24 0 L17 AND TANIGUCHI, M?/AU

=> d l17, ibib abs hitstr, 1-13

L17 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:464621 HCAPLUS

DOCUMENT NUMBER: 144:488655

TITLE: Preparation of 8H-imidazo[4,5-d]thiazolo[4,5-b]pyridine derivatives as IKK inhibitors for treatment of inflammatory and immune diseases

INVENTOR(S): Dyckman, Alaric; Pitts, William J.; Belema, Makonen; Gill, Patrice; Kempson, James; Qiu, Yuping; Quesnelle, Claude; Spergel, Steven H.; Zusi, F. Christopher

Updated Search

09830923


PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 67 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006106051	A1	20060518	US 2005-272401	20051110
WO 2006053120	A1	20060518	WO 2005-US40726	20051110


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-627761P P 20041112  
 OTHER SOURCE(S): MARPAT 144:488655  
 GI



I



II

AB The title 8H-imidazo[4,5-d]thiazolo[4,5-b]pyridine derivs. I [wherein R1 = H, alkyl, alkenyl, or alkynyl; R2 = H, halo, CN, (un)substituted alkyl, alkenyl, alkoxy, aryloxy, etc.; R3 = 3-substituted phenyl], or their enantiomers, diastereomers, and salts thereof were prepared as IKK inhibitors for the treatment of inflammatory and immune diseases. For example, II was prepared in a multi-step synthesis. The compds. showed inhibitory activity against IKK, IκB, NF-κB, and/or TNF-α (no data).

IT 887253-17-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazothiazolopyridine derivs. as IKK inhibitors for treatment of inflammatory and immune diseases)


RN 887253-17-0 HCAPLUS

CN 3-Pyridinecarboxamide, 2,6-dimethoxy-N-[(1S)-1-[3-(8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-2-yl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

09830923



L17 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:193407 HCAPLUS

DOCUMENT NUMBER: 144:273163

TITLE: Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers

INVENTOR(S): Tachdjian, Catherine; Patron, Andrew P.; Qi, Ming; Adamski-Werner, Sara L.; Tang, Xiao-Qing; Chen, Qing; Darmohusodo, Vincent; Lebl-Rinnova, Marketa; Priest, Chad

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 168 pp., Cont.-in-part of U.S. Ser. No. 913,303.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006045953	A1	20060302	US 2005-51567	20050204
US 2005084506	A1	20050421	US 2004-913303	20040806
WO 2005041684	A2	20050512	WO 2004-US25419	20040806
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2006084246	A2	20060810	WO 2006-US4132	20060206
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,			

Updated Search

09830923

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2004-913303	A2 20040806
WO 2004-US25419	A2 20040806
US 2003-494071P	P 20030806
US 2004-552064P	P 20040309
US 2005-51567	A 20050204

OTHER SOURCE(S): MARPAT 144:273163

AB Non-natural amide compds. added to food, beverages, or pharmaceuticals at concns. preferably on the order of 100 ppm or lower may serve as savory (umami) or sweet taste modifiers, savory or sweet flavoring agents, and savory or sweet flavor enhancers. They may also act in the presence of, or in mixts. with, conventional flavoring agents such as monosodium glutamate or known natural and artificial sweeteners. Thus, 3  $\mu$ M N1-(2,4-dimethoxybenzyl)-N2-(2-(pyridin-2-yl)ethyl)oxalamide enhanced the savory taste of glutamate in low-sodium tomato juice by 1.4 to 1.5-fold.


IT 851669-82-4P

RL: FFD (Food or feed use); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(aromatic amides and ureas as sweetness or umami flavor modifiers)

RN 851669-82-4 HCAPLUS

CN D-Leucine, N-[(2,6-dimethoxy-4-pyridinyl)carbonyl]-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:696876 HCAPLUS

DOCUMENT NUMBER: 143:193910

TITLE: Preparation of herbicidal amides

INVENTOR(S): Hanagan, Mary Ann; Selby, Thomas Paul; Sharpe, Paula Louise; Sheth, Ritesh B.; Stevenson, Thomas Martin

PATENT ASSIGNEE(S): E.I. Dupont de Nemours and Company, USA

SOURCE: PCT Int. Appl., 248 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070889	A1	20050804	WO 2005-US2147	20050121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

Updated Search

09830923

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2004-539073P

P 20040123






US 2004-607277P

P 20040903

OTHER SOURCE(S):

MARPAT 143:193910

GI



AB The title compds. I [ $J = II, III, IV, V$ ;  $Y = O, SOn, NR_8$ ;  $R = H$ , alkoxymethyl, alkylcarbonyl, alkoxycarbonyl;  $R_1 = H$ , alkyl;  $R_2 = H$ , alkyl, haloalkyl, etc.;  $R_3 = halo, CN, NO_2$ , etc.; two adjacent  $R_3$  are taken together as  $OCH_2O, O(CHMe)O, O(CMe_2)O$ , etc.;  $R_4 = alkyl, cycloalkyl, alkylcycloalkyl$ , etc.;  $R_5 = H, halo, alkyl$ , etc.;  $R_6 = H, halo, CN$ , etc.;  $R_6a = alkyl, haloalkyl, alkenyl$ , etc.;  $R_7 = H, alkyl, haloalkyl$ , etc.;  $R_8 = H, alkyl, alkylcarbonyl$ , etc.;  $n = 0-1$ ;  $m = 0-5$ ;  $q = 0-1$ ] which are useful for controlling undesired vegetation (biol. data given), were prepared E.g., a 2-step synthesis of VI, starting from 2,4-dichloro-6-methyl-3-pyridinecarboxylic acid and 1-propanol, was given. Also disclosed are compns. comprising the compds. I and a method for controlling undesired vegetation which involves contacting the vegetation or its environment with an effective amount of a compound I. Also disclosed are compns. comprising a compound I and at least one addnl. active

Updated Search

09830923

ingredient selected from the group consisting of an other herbicide and a herbicide safener.

IT 861894-48-6P


RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of herbicidal amides)

RN 861894-48-6 HCAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[(1S)-1-(4-fluorophenyl)ethyl]-2,4-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:405341 HCAPLUS

DOCUMENT NUMBER: 142:462667

TITLE: Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

INVENTOR(S): Tachdjian, Catherine; Patron, Andrew P.; Adamski-Werner, Sara L.; Bakir, Farid; Chen, Qing; Darmohusodo, Vincent; Hobson, Stephen Terrence; Li, Xiadong; Qi, Ming; Rogers, Daniel Harry; Rinnova, Marketa; Servant, Guy; Tang, Xiao-Qing; Zoller, Mark; Wallace, Mark; Xing, Amy; Gubernator, Klaus

PATENT ASSIGNEE(S): Senomyx Inc., USA

SOURCE: PCT Int. Appl., 262 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041684	A2	20050512	WO 2004-US25419	20040806
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

Updated Search

09830923

AU 2004285410	A1	20050512	AU 2004-285410	20040806
CA 2535036	AA	20050512	CA 2004-2535036	20040806
EP 1659881	A2	20060531	EP 2004-816798	20040806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2006045953	A1	20060302	US 2005-51567	20050204
PRIORITY APPLN. INFO.:			US 2003-494071P	P 20030806
			US 2004-552064P	P 20040309
			US 2004-913303	A2 20040806
			WO 2004-US25419	W 20040806

OTHER SOURCE(S): MARPAT 142:462667


AB Flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or trite enhancer, more particularly, savory (the 'umami' taste of monosodium glutamate) or sweet taste modifiers, - savory or sweet flavoring agents and savory or sweet flavor enhancers, were prepared for food, beverages, and other comestible or orally administered medicinal products or compns. Thus, non-naturally occurring, non-peptide arride compds. and amide derivs., such as oxalamides, ureas, and acrylamides, were prepared

IT 851669-82-4P  
RL: FFD (Food or feed use); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and their use)

RN 851669-82-4 HCAPLUS

CN D-Leucine, N-[(2,6-dimethoxy-4-pyridinyl)carbonyl]-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:912843 HCAPLUS

DOCUMENT NUMBER: 139:381756

TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua



Updated Search

09830923

PATENT ASSIGNEE(S): Schering Corporation, USA; Dendreon Corporation  
 SOURCE: U.S. Pat. Appl. Publ., 629 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003216325	A1	20031120	US 2001-908955	20010719
US 2004254117	A9	20041216		
US 7012066	B2	20060314		
CN 1498224	A	20040519	CN 2001-813111	20010719
ZA 2002010312	A	20040329	ZA 2002-10312	20021219
PRIORITY APPLN. INFO.:			US 2000-220108P	P 20000721
OTHER SOURCE(S):	MARPAT 139:381756			

GI



AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N,

Updated Search

09830923

alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO<sub>2</sub>, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO<sub>2</sub>, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease. Thus, peptide II was prepared by the solid-phase method and showed K<sub>i</sub> = 1-100 nM (category A) in the HCV continuous assay.

IT 394720-42-4P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394720-42-4 HCAPLUS

CN Glycine, N-[(3,6-dimethoxy-2-pyridinyl)carbonyl]-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 2-propenyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

=CH<sub>2</sub>

REFERENCE COUNT: 111 THERE ARE 111 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591204 HCAPLUS

DOCUMENT NUMBER: 139:149928

TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

Updated Search

09830923

INVENTOR(S) : Saksena, Anil K.; Girijavallabh, Viyyoor M.; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, George F.; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Wong, Jesse K.; Nair, Latha G.

PATENT ASSIGNEE(S) : Schering Corporation, USA; Corvas International, Inc.; Dendreon Corp.

SOURCE: PCT Int. Appl., 633 pp.  
CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062265	A2	20030731	WO 2003-US1430	20030116
WO 2003062265	A3	20040916		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473032	AA	20030731	CA 2003-2473032	20030116
EP 1481000	A2	20041201	EP 2003-731956	20030116
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003006931	A	20050419	BR 2003-6931	20030116
CN 1633446	A	20050629	CN 2003-805933	20030116
JP 2005524628	T2	20050818	JP 2003-562142	20030116
NO 2004002792	A	20041015	NO 2004-2792	20040702
PRIORITY APPLN. INFO.:			US 2002-52386	A 20020118
			WO 2003-US1430	W 20030116
OTHER SOURCE(S) :	MARPAT 139:149928			
GI				



AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is selected from O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease. Thus, peptide II was prepared and showed  $K_i = 1-100$  nM (category A) in the HCV continuous assay.

IT 394720-42-4P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


```
(preparation of peptides as NS3-serine protease inhibitors of hepatitis C
virus)
```

RN 394720-42-4 HCAPLUS

CN Glycine, N-[(3,6-dimethoxy-2-pyridinyl)carbonyl]-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 2-propenyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


 $\text{=CH}_2$ 

L17 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:90062 HCAPLUS

DOCUMENT NUMBER: 136:167698

TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-Tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal N.; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.

SOURCE: PCT Int. Appl., 536 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008244	A2	20020131	WO 2001-US22678	20010719
WO 2002008244	A3	20030619		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

09830923

CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,  
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,  
MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG



CA 2410662	AA	20020131	CA 2001-2410662	20010719
AU 2001076988	A5	20020205	AU 2001-76988	20010719
BR 2001012540	A	20030624	BR 2001-12540	20010719
EP 1385870	A2	20040204	EP 2001-954764	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004504404	T2	20040212	JP 2002-514149	20010719
CN 1498224	A	20040519	CN 2001-813111	20010719
NZ 523782	A	20051028	NZ 2001-523782	20010719
ZA 2002010312	A	20040329	ZA 2002-10312	20021219
NO 2003000272	A	20030321	NO 2003-272	20030120

PRIORITY APPLN. INFO.:

US 2000-220108P	P	20000721
WO 2001-US22678	W	20010719

OTHER SOURCE(S): MARPAT 136:167698

GI



AB Peptides I were prepared wherein Y is alkyl, alkyl-aryl, heteroaryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy,, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino and heterocycloalkylamino; R1 is acyl, borate; Z is selected from O, N, CH or CR; W, Q, G, J, L, M independently maybe present or absent; W is C=O, C=S, C(=N-CN), or SO; Q is CH, N, P, alkylidene, O, amine,S, or SO; A is O, CH, alkylidene, amine, S, SO or bond; E is CH, N, alkylidene, or double bond; G is alkylidene; J is alkylidene, SO, NH, NR, O; L is CH, alkylidene, O, S or NR; M is O, NR,S, SO, alkylidene; p is 0 to 6; and R-R4 are independently selected from the

Updated Search

group consisting of H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halogen; (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease. Thus peptide II was prepared and tested as antiviral agent and NS3-serine protease inhibitors of hepatitis C virus with  $K_i$  ranges in category A = 1-100 nM; category B = 101-1,000 nM; category C > 1000 nM. Also disclosed is the use of I for the manufacture of a medicament for treating HCV, AIDS, and related disorders.

IT 394720-42-4P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394720-42-4 HCAPLUS

CN Glycine, N-[(3,6-dimethoxy-2-pyridinyl)carbonyl]-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 2-propenyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

=CH<sub>2</sub>

L17 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:900620 HCAPLUS

DOCUMENT NUMBER: 134:56577



TITLE: Pyridinecarboxamides and their use as plant protection

Updated Search

09830923

INVENTOR(S) : agents  
Backhaus, Dirk; Jordan, Stephan; Boie, Christiane;  
Schneider, Udo; Gayer, Herbert; Vaupel, Martin;  
Mauler-Machnik, Astrid; Wachendorff-Neumann, Ulrike;  
Kuck, Karl-Heinz  
PATENT ASSIGNEE(S) : Bayer A.-G., Germany  
SOURCE: PCT Int. Appl., 63 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076979	A1	20001221	WO 2000-EP4870	20000529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 19958166 A1 20001214 DE 1999-19958166 19991202 PRIORITY APPLN. INFO.: DE 1999-19926174 A 19990609 DE 1999-19958166 A 19991202 OTHER SOURCE(S) : MARPAT 134:56577 GI				



AB Pyridinecarboxamides I [A = bond, (un)substituted alkylene, heteroalkylene; R1 = (un)substituted cycloalkyl, cycloalkenyl, aryl, heterocyclyl; R2 = H, acyl, alkoxy-carbonyl] were prepared for use as agricultural fungicides. Thus, the amide II was obtained by amidation. II was ≥91% effective against Botrytis on beans at 500 g/ha.


IT 313643-68-4P 313643-71-9P  
 RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyridinecarboxamides as agricultural fungicides)

Updated Search

09830923


RN 313643-68-4 HCAPLUS

CN Propanoic acid, 2-methyl-, 4-methoxy-2-[[[1-(4-phenoxyphenyl)ethyl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)



RN 313643-71-9 HCAPLUS

CN 2-Pyridinecarboxamide, 3-(acetyloxy)-4-methoxy-N-[1-(4-phenoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:819241 HCAPLUS

DOCUMENT NUMBER: 132:64530

TITLE: Preparation of diacyl hydrazine compounds as protease inhibitors

INVENTOR(S): Halbert, Stacie Marie; Michaud, Evelyne; Thompson, Scott Kevin; Veber, Daniel Frank

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 167 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966925	A1	19991229	WO 1999-US14561	19990624
W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2335876	AA	19991229	CA 1999-2335876	19990624
AU 9947237	A1	20000110	AU 1999-47237	19990624

Updated Search

EP 1093367	A1	20010425	EP 1999-930779		19990624
R: BE, CH, DE, ES, FR, GB, IT, LI, NL					
JP 2002518444	T2	20020625	JP 2000-555611		19990624
PRIORITY APPLN. INFO.:			US 1998-90493P	P	19980624
			WO 1999-US14561	W	19990624
OTHER SOURCE(S):		MARPAT 132:64530			
GI					



AB The present invention provides compounds. I [L = C2-6 alkyl, Ar- or Het-C0-6 alkyl, CHR4NR5R6, CHR4Ar, CHR4OAr, NR4R7; X, Y, Z = N, O, S, CR10; R1, R2, R5, R10 = H, C1-6 alkyl, C2-6 alkenyl, Ar- or Het-C0-6 alkyl; R3 = C3-6 alkyl, Ar, Het, heterocycle Q, etc.; R4 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ar- or Het-C0-6 alkyl, etc.; R6 = R14 or an acyl group such as R14CO, R14C(S), R14OCO (R14 = C1-6 alkyl, C2-6 alkenyl, Ar- or Het C0-6 alkyl); R7 = C1-6 alkyl, C1-6 alkenyl, C3-6 cycloalkyl-, Ar-, or Het-C0-6 alkyl], which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis, gingival disease, and arthritis. Thus, N-[2-[N-cyclopropyl-N-(cyclopropylmethyl)amino]thiazol-4-ylcarbonyl]-N'-[N-(6-methyl-3-pyridinylmethoxycarbonyl)-L-β-tert-butylalanyl]hydrazide was prepared via sequential reactions of Et 6-nicotinate, L-β-tert-butylalanine, cyclopropylamine, cyclopropylcarboxaldehyde, benzoyl isothiocyanate, and Et bromopyruvate.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of diacyl hydrazine compds. as protease inhibitors)

CN 4-Thiazolecarboxylic acid, 2-[cyclopropyl(2-methylpropyl)amino]-,  
2-[(2S)-2-[[[(2,6-dimethoxy-3-pyridinyl)carbonyl]amino]-4-methyl-1-oxopentyl]hydrazide (9CI) (CA INDEX NAME)

COc1ccc(NC(=O)N[C@@H](C(C)C)C(=O)NNC(=O)c2cnc(NC(C)C)cs2)c(C)c1

Updated Search

09830923

DOCUMENT NUMBER: 132:426  
 TITLE: Diacyl carbohydrazide compounds as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation  
 INVENTOR(S): Halbert, Stacie Marie; Thompson, Scott Kevin; Veber, Daniel Frank  
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 74 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959570	A1	19991125	WO 1998-US17275	19980820
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332492	AA	19991125	CA 1998-2332492	19980820
AU 9891102	A1	19991206	AU 1998-91102	19980820
EP 1079821	A1	20010307	EP 1998-943273	19980820
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2002515428	T2	20020528	JP 2000-549235	19980820
PRIORITY APPLN. INFO.:			US 1998-86553P	P 19980521
			WO 1998-US17275	W 19980820

OTHER SOURCE(S): MARPAT 132:426

AB The present invention provides diacyl carbohydrazide compds., and pharmaceutically acceptable salts, hydrates and solvates thereof, which inhibit proteases, including cathepsin K, pharmaceutical compns. of such compds., novel intermediates of such compds., and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

IT 250726-27-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (diacyl carbohydrazide compds. as protease inhibitors for treating diseases of excessive bone loss or cartilage or matrix degradation)


RN 250726-27-3 HCAPLUS

CN Benzeneacetic acid, 3-(2-pyridinyl)-, 2-[[2-[(2S)-2-[[2,6-dimethoxy-3-pyridinyl]carbonyl]amino]-4-methyl-1-oxopentyl]hydrazino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

09830923



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:268513 HCAPLUS

DOCUMENT NUMBER: 128:321945

TITLE: Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus NS3 protease  
INVENTOR(S): Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2268391	AA	19980430	CA 1997-2268391	19971017
ZA 9709327	A	19980511	ZA 1997-9327	19971017
AU 9851477	A1	19980515	AU 1998-51477	19971017
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017
EP 932617	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 183120	A	19990911	IN 1997-CA1951	19971017
BR 9712544	A	19991019	BR 1997-12544	19971017
CN 1238780	A	19991215	CN 1997-180151	19971017
CN 1133649	B	20040107		
NZ 335276	A	20000929	NZ 1997-335276	19971017
JP 2001502694	T2	20010227	JP 1998-519568	19971017
EP 1136498	A1	20010926	EP 2001-109433	19971017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

Updated Search

09830923

AP 1019	A	20011016	AP 1999-1512	19971017
W: GH, KE, LS, MW, SD, SZ, UG, ZW				
AT 212037	E	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
EE 4023	B1	20030415	EE 1999-161	19971017
TW 530065	B	20030501	TW 1997-86115382	19971018
NO 9901832	A	19990617	NO 1999-1832	19990416
US 6265380	B1	20010724	US 1999-293247	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417
HK 1023779	A1	20020927	HK 2000-100690	20000203
US 2002032175	A1	20020314	US 2001-875390	20010606
US 6617309	B2	20030909		
US 2004266731	A1	20041230	US 2003-607716	20030627
PRIORITY APPLN. INFO.:			US 1996-28290P	P 19961018
			EP 1997-946273	A3 19971017
			WO 1997-US18968	W 19971017
			US 1999-293247	A 19990416
			US 2001-875390	A3 20010606
OTHER SOURCE(S):	MARPAT 128:321945			
GI				



AB The present invention relates to compds. I [G1 = SH, OH, SMe, alkenyl, alkynyl, CF3, C1-2 alkoxy, C1-2 alkylthio, (un)substituted C1-3 alkyl; W1 = COCF2CH2N(G4)U, CHO, COG2, COCF2CF3, COCOG2, COCO2G2, B(Q1)2; G2 = alkyl, aryl, aralkyl, (un)substituted mono-, bi-, or tricyclic heterocycle; G4 = alky, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, etc.; Q1 = OH, alkoxy,

Updated Search

aryloxy, or Q1-Q1 form a 5-7 membered ring; U = H, G9CO, G9SO2, G9COCO, (G9)2NCOCO, (G9)2NSO2, (G9)2NCO, G9O2C; G9 = H, alkyl, carboxyalkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, heterocycloalkyl, etc; or G9-G9 form a ring; E4 = bond,  $\alpha$ -amino acid residue, heterocyclic amino acid; E5-E8 = independently bond, amino acid residue; 1-2 peptide bonds between E5-E8 may be reduced], methods and pharmaceutical compns. for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compds., and the compns. and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus. Thus, peptide aldehyde II was prepared using solid-phase methods on a benzhydrylamine resin and tert-butoxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) protection starting from protected hydrazone III. Nearly 200 compds. I were prepared and tested for hepatitis C virus NS3 protease inhibitory activity, with II exhibiting  $K_i < 1 \mu\text{M}$  in an in vitro assay.

IT 207001-81-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of peptide analogs as hepatitis C virus NS3 protease inhibitors)

RN 207001-81-8 HCAPLUS

CN L-Leucinamide, N-[(2,6-dimethoxy-3-pyridinyl)carbonyl]-L-valyl-L-valyl-N-[(1S)-1-formylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1969:114460 HCAPLUS

DOCUMENT NUMBER: 70:114460

TITLE: Polarographic study of some nitrogen-containing heterocycles

AUTHOR(S): Mikhailova, T. A.; Kudryashova, N. I.; Khromov-Borisov, N. V.

CORPORATE SOURCE: Inst. Eksp. Med., Leningrad, USSR

SOURCE: Zhurnal Obshchei Khimii (1969), 39(1), 26-30  
CODEN: ZOKHA4; ISSN: 0044-460X

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB Polarographic halfwave potentials were reported in the pH range of


Updated Search

1.85-11.6 for pyridine, quinoline, acridine, their 4-carboxylic acids, and the amides of these acids with N-CHMeCH<sub>2</sub>Ph grouping. Also included were data on N-(1-methyl-2-phenylethyl)amides of isonicotinic acid with the following 2,6-ring substituents: H, H; Cl, Cl; MeO, MeO; Et<sub>2</sub>N, Et<sub>2</sub>N; Cl, MeO; Cl, Et<sub>2</sub>N. N,N-diethylisonicotinamide with the following 2,6-substituents were also reported: H, H; Cl, Cl; Cl, MeO; MeO, MeO; Cl, Et<sub>2</sub>N; Et<sub>2</sub>N, Et<sub>2</sub>N. The main center of reaction in these compds. is the C:N link which gives the 1st polarographic wave at any pH value. Introduction of 4-substituents with electron-acceptor properties serves to lower the halfwave potential; introduction of electron donor groups in 2,6-positions raises the halfwave potential. The CO<sub>2</sub>H and CONHR groups cause a 2nd polarographic wave in neutral medium only. Treating the acyl chloride with Et<sub>2</sub>NH in C<sub>6</sub>H<sub>6</sub> gave the diethylamides of: isonicotinic acid, b<sub>3</sub> 133°, n<sub>20D</sub> 1.5238; 2,6-dichloroisonicotinic acid (I), m. 82-4°; 2-chloro-6-methoxy analog, b<sub>3</sub> 153°; and the 2,6-dimethoxy analog, m. 87-8°. Heating the diethylamide of I with Et<sub>2</sub>NH at 100° 1 day gave the diethylamide of 2-chloro-6-diethylaminoisonicotinic acid, b<sub>4</sub> 182-4°; similarly, by heating 26 hrs. at 200°, the 2,6-bis(diethylamino)analog, m. 54-6°, b<sub>3</sub> 185-7°, was prepared

IT 15855-04-6

RL: PRP (Properties)  
(polarography of)

RN 15855-04-6 HCAPLUS

CN Isonicotinamide, 2,6-dimethoxy-N-(α-methylphenethyl)- (8CI) (CA  
INDEX NAME)

L17 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1967:482064 HCAPLUS

DOCUMENT NUMBER: 67:82064

TITLE: Drugs from β-phenylisopropylamines. I.  
Derivatives containing a pyridine ring

AUTHOR(S): Kudryashova, N. I.; Khromov-Borisov, N. V.

CORPORATE SOURCE: Inst. Eksperim. Med. Akad. Med. Nauk., Leningrad, USSR

SOURCE: Zhurnal Organicheskoi Khimii (1967), 3(6), 1117-21

CODEN: ZORKAE; ISSN: 0514-7492

DOCUMENT TYPE: Journal


LANGUAGE: Russian

AB A series of the title compds. of general formula PhCH<sub>2</sub>CMeHNHR (I) was synthesized. Compds. I (R = isonicotinyl) and I (R = 4-pyridyl) have sedative and hypotensive activities. The compds. were prepared by treating 2-R<sub>1</sub>-substituted, 6-R<sub>2</sub>-substituted isonicotinyl chloride (II) with PhCH<sub>2</sub>CMeHNH<sub>2</sub>. For example, to 15 g. isonicotinic acid 45 ml. SOCl<sub>2</sub> was added slowly. The mixture was boiled to dissolve all the solids and evaporated to dryness in vacuum. The residue was dissolved in 60 ml. anhydrous benzene and 55 ml. PhCH<sub>2</sub>CMeHNH<sub>2</sub> was added slowly. The mixture was refluxed 3 hrs., washed with water, dried with K<sub>2</sub>CO<sub>3</sub>, and evaporated in vacuo. The residue was

09830923

crystallized from MeOH to give 50.6% I (R = isonicotinyl) m. 11-12.5° (HCl salt m. 92-4°). II (R1 = R2 = Cl), m. 208-9° (alc.-water), was prepared in 91% yield by action of POCl3 on II (R1 = R2 = OH). Heating II (R1 = R2 = Cl) with NaOMe gave 93.3% II (R1 = Cl, R2 = OMe) m. 212-13° (alc.-water), and II (R1 = R2 = OMe), m. 226.5-28° (MeOH) (yield not given). Treating II with PhCH2CMeHNH2 gave the following I (R, % yield, and m.p. given): 2,6-dichloroisonicotinyl, 96.3, 137.5-38° (alc.-water); 2,6-dimethoxyisonicotinyl, 62, 88-91° (AcMe); 2-chloro-6-methoxyisonicotinyl, 60.8, 102-4° (alc.-water). Reaction of cinchoninyl chloride (prepared in situ from cinchoninic acid and SOCl2) with PhCH2CMeHNH2 gave 74.1% I (R = cinchoninyl), m. 140-4° (alc.-water). (HCl salt m. 205-7°). Similarly, I (R = 9-acridinylcarbonyl), m. 200-2° (alc.-water) (yield 84.5%) (HCl salt m. 282-3°) was prepared. Heating a mixture of 2.85 g. I (R = 2,6-dichloroisonicotinyl) and 15 ml. Et2NH in a sealed tube 15 hrs. at 195-200° gave 70.1% I (R = 2,6-diethylaminoisonicotinyl), m. 167-9° (AcMe). The above sealed-tube reaction with .apprx.1/2 the amount of Et2NH gave 89.6% I (R = 2-chloro-6-ethylaminoisonicotinyl), m. 136-7° (alc.-water). Refluxing 2 hrs. at 200-5° a mixture of 6.05 g. PhCH2CMeHNH2.HCl with 6.22 g. 4-phenoxy pyridine, followed by dissoln. in water, steam distillation (to remove PhCH2CMeHNH2), acidification, 2nd steam distillation (to remove PhOH), neutralization, and crystallization of the organic layer gave 55.7% I (R = 4-pyridyl), m. 122-3° (alc.-water).

IT 15855-04-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 15855-04-6 HCAPLUS  
 CN Isonicotinamide, 2,6-dimethoxy-N-(α-methylphenethyl)- (8CI) (CA INDEX NAME)



=> file caold  
 COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE ENTRY	TOTAL SESSION
79.08	933.02
SINCE FILE ENTRY	TOTAL SESSION
-9.75	-9.75

FILE 'CAOLD' ENTERED AT 12:05:33 ON 06 SEP 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Updated Search

09830923

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 11:42:01 ON 06 SEP 2006)

FILE 'REGISTRY' ENTERED AT 11:42:08 ON 06 SEP 2006

L1	STRUCTURE UPLOADED
L2	2 S L1
L3	STRUCTURE UPLOADED
L4	0 S L3
L5	0 S L3 FULL
L6	STRUCTURE UPLOADED
L7	2 S L6
L8	383 S L6 FULL

FILE 'HCAPLUS' ENTERED AT 11:54:10 ON 06 SEP 2006

L9	139 S L8
----	----------

FILE 'REGISTRY' ENTERED AT 11:55:51 ON 06 SEP 2006

L10	STRUCTURE UPLOADED
L11	0 S L10
L12	0 S L10 FULL
L13	STRUCTURE UPLOADED
L14	2 S L13
L15	10 S L13 FULL
L16	10 S L14 FULL

FILE 'HCAPLUS' ENTERED AT 12:02:18 ON 06 SEP 2006

L17	13 S L15
L18	0 S L17 AND IMAMURA, K?/AU
L19	0 S L17 AND MITOMO, K?/AU
L20	0 S L17 AND YAMADA, N?/AU
L21	0 S L17 AND TERAOKA, T?/AU
L22	0 S L17 AND SAKANAKA, O?/AU
L23	0 S L17 AND KURIHARA, H?/AU
L24	0 S L17 AND TANIGUCHI, M?/AU

FILE 'CAOLD' ENTERED AT 12:05:33 ON 06 SEP 2006

=> s l16

L25	0 L16
-----	-------

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

Updated Search

09830923

	ENTRY	SESSION
FULL ESTIMATED COST	0.44	933.46
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-9.75

FILE 'HCAPLUS' ENTERED AT 12:05:45 ON 06 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Sep 2006 VOL 145 ISS 11  
FILE LAST UPDATED: 5 Sep 2006 (20060905/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s imamura, k?/au and mitomo, k?/au and yamada, n?/au and yamamoto, k?/au and teraoka, t?/au and sakanaka, o?/au and kurihara, h?/au and taniguchi, m?/au

1427 IMAMURA, K?/AU  
43 MITOMO, K?/AU  
3789 YAMADA, N?/AU  
18126 YAMAMOTO, K?/AU  
382 TERAOKA, T?/AU  
25 SAKANAKA, O?/AU  
1421 KURIHARA, H?/AU  
3956 TANIGUCHI, M?/AU

L26 1 IMAMURA, K?/AU AND MITOMO, K?/AU AND YAMADA, N?/AU AND YAMAMOTO, K?/AU AND TERAOKA, T?/AU AND SAKANAKA, O?/AU AND KURIHARA, H?/AU AND TANIGUCHI, M?/AU

=> d l26, ibib abs hitstr, 1

L26 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:314676 HCAPLUS

DOCUMENT NUMBER: 132:334362

TITLE: Preparation of picolinamide derivatives and pest controllers containing the same as the active ingredient

INVENTOR(S): Imamura, Keiichi; Mitomo, Kouichi;  
Yamada, Natsuko; Yamamoto, Kazumi;  
Teraoka, Takeshi; Sakanaka, Osamu;  
Kurihara, Hiroshi; Taniguchi, Makoto

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan


SOURCE: PCT Int. Appl., 98 pp.

Updated Search

09830923

DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026191	A1	20000511	WO 1999-JP6142	19991104
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2353627	AA	20000511	CA 1999-2353627	19991104
EP 1134214	A1	20010919	EP 1999-954375	19991104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 771975	B2	20040408	AU 2000-10768	19991104
PRIORITY APPLN. INFO.:			JP 1998-313688	A 19981104
			WO 1999-JP6142	W 19991104
OTHER SOURCE(S):		MARPAT 132:334362		
GI				



AB Described are novel compds. of general formula [I; wherein A is a bond or optionally substituted alkylene; R1 is one or more groups which may be the same or different from each other and are selected from among hydrogen, alkoxy and haloalkoxy; R2 is hydrogen, (substituted) benzyl, (substituted) alkyl or (substituted) alkanoyl; and R3 is hydrogen, (substituted) cycloalkyl, (substituted) cycloalkenyl, (substituted) aryl, or a (substituted) heterocyclic group, with the proviso that the cases wherein R1 is hydrogen, A is a free valency or methylene, and R3 is Ph or cyclohexyl or those wherein A is alkylene and R3 is hydrogen are excepted.], pest controllers such as plant fungicides, insecticides, and herbicides containing the same; and a process for the preparation of the compds.

Thus, a solution of 1.85 g 4-phenoxyaniline in 25 mL DMF was added dropwise to a suspension of 1.39 g 3-hydroxypicolinic acid, 1.95 g carbonyl diimidazole, and 30 mL DMF and stirred overnight to give 41% 3-hydroxy-4'-phenoxy-picolinanilide (II). II at 100 ppm protected 80-100% rice seedlings against *Pyricularia oryzae*.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Updated Search